文献类型：期刊文献

英文题名：Screening study of serum thrombosis-related target proteins using a specific dabigatran-functionalized material

作者：Dong, Shiqi[1];Wang, Xiaoyan[2];Niu, Hui[1];Qian, Junhong[2];Zhang, Lingyi[2];Zhang, Weibing[2]

机构：[1]Dalian Univ Technol, Sch Chem Engn, State Key Lab Fine Chem, Dalian 116024, Peoples R China;[2]East China Univ Sci & Technol, Sch Chem & Mol Engn, Shanghai Key Lab Funct Mat Chem, Shanghai 200237, Peoples R China

年份：2026

外文期刊名：ANALYTICAL METHODS

收录：;EI(收录号：20263121207183);Scopus(收录号：2-s2.0-105046044684);WOS:【SCI-EXPANDED(收录号:WOS:001825488700001)】；

基金：Financial support was from the Fundamental Research Funds for the Central Universities (JKJ01261717). The authors sincerely thank all patients for their generous donation of the samples.

语种：英文

外文关键词：Body fluids - Diagnosis - Disease control - Diseases - Drug discovery - Drug interactions - Iron oxides - Magnetic materials - Patient treatment - Screening - SiO2 nanoparticles

摘要：A drug-related protein profiling strategy was developed based on drug-protein interactions, utilizing a magnetic adsorbent modified with dabigatran (Fe3O4@SiO2@DBG). Dabigatran (DBG), the hydrolytic product of dabigatran etexilate, which is a drug for thromboembolic disease treatment, was covalently immobilized on the surface of the Fe3O4@SiO2-NH2 nanomaterial via amide bonds to screen drug-associated proteins in patient serum based on protein-drug interactions. Healthy human serum was first used as a model sample to evaluate the strategy and optimize the screen procedure. Subsequently, the method was applied to screen drug-related proteins in serum samples from patients with hyperlipidemia/thrombosis/cardiovascular disease (HTC) and healthy controls (HC). A total of 26 differential proteins were identified. Further GO functional annotation and KEGG pathway analyses revealed that these differential proteins and their involved pathways were highly associated with the regulation of metabolic processes and signalling pathways related to HTC diseases, providing guidance for the screening of drug targets or biomarkers of thromboembolic diseases. Collectively, this interaction-oriented protein screening approach provides an innovative technical platform for subsequent mechanism research and related drug development.